Meanwhile, Synagis is likely to be replaced by Beyfortus and clesrovimab for preventing RSV infections in infants, said Anaelle Tannen, Infectious Disease Analyst at GlobalData. Key opinion ...

AstraZeneca has agreed to sell the rights to its drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) for an upfront $1.5 billion in cash and shares, plus certain conditional payments.

Merck, aiming for pediatric use, would still join a wider market with the three new vaccines made by Pfizer, GSK and Moderna, as well as earlier monoclonal antibodies like Synagis and Beyfortus.

New data from the phase 2/3 MEDLEY trial showed that nirsevimab (formerly MEDI8897) was at least as effective as the older RSV antibody Synagis (palivizumab) in protecting preterm infants or those ...